It started with bruises on my mum’s arms. They were small, purple, and red, as if she had fallen down. While we were still trying…
Myeloma
The U.S. Food and Drug Administration (FDA) has granted fast track status to Opna Bio‘s OPN-6602 as a potential treatment for people…
Note: This column describes the author’s experience with several multiple myeloma treatments. Not everyone will have the same response to treatment. Consult your doctor before…
Her name badge looked so common and ordinary; it was a tiny, plastic square attached to the hem of a pocket on her scrubs. But…
I used to pride myself on my memory. Growing up, I remembered every detail of things that happened. Sometimes I would – very annoyingly —…
I can vividly recall an incident that occurred inside the infusion room one day last November. It was the third hour of a four-hour drip…
The first patient has been dosed in a Phase 2 trial testing an all-oral, triple-combination treatment that includes Cellcentric’s investigational therapy inobrodib in people…
A few weeks ago, I wrote about the annual challenge I face during the season of Lent: the temptation of Thin Mints. The Thin…
Recently, I’ve observed a new type of quietness between my mum and me. It is not the usual silence that arises after a myeloma…
A European Medicines Agency (EMA) panel has recommended approval of a subcutaneous (under-the-skin) version of Sarclisa (isatuximab), an approved myeloma treatment sold by Sanofi. The…
